# ALX-0061 Phase I Bioavailability Study in Healthy Volunteers

> **NCT02101073** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 70 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ALX-0061
- **BIOLOGICAL:** ALX-0061

## Key facts

- **NCT ID:** NCT02101073
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-31
- **Primary completion:** 2014-07-31
- **Final completion:** 2014-07-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101073, "ALX-0061 Phase I Bioavailability Study in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02101073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*